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Currently,  the golden  standard  for  the  puriﬁcation  of  recombinant  humanized  antibodies  (rhAbs)  from
CHO  cell  culture  is  protein  A  chromatography.  However,  due  to  increasing  rhAbs  titers  alternative  meth-
ods  have  come  into  focus.  A new  strategy  for puriﬁcation  of  recombinant  human  antibodies  from  CHO  cell
culture  supernatant  based  on  cold  ethanol  precipitation  (CEP)  and  CaCl2 precipitation  has  been  developed.
This  method  is based  on  the  cold  ethanol  precipitation,  the  process  used  for puriﬁcation  of  antibodies
and  other  components  from  blood  plasma.  We  proof  the  applicability  of  the  developed  process  for  fourHO
ecombinant antibodies
old ethanol precipitation
rganic solvent
onolith
different  antibodies  resulting  in  similar  yield  and  purity  as  a protein  A chromatography  based  process.
This  process  can  be further  improved  using  an  anion-exchange  chromatography  in ﬂowthrough  mode
e.g.  a monolith  as  last  step  so  that  residual  host  cell  protein  is reduced  to a minimum.  Beside  the  ethanol
based  process,  our data  also  suggest  that  ethanol  could  be  replaced  with  methanol  or  isopropanol.  The
process  is suited  for  continuous  operation.
© 2014  The  Authors.  Published  by  Elsevier  B.V.  This  is  an  open  access  article  under the  CC  BY-NC-ND. Introduction
Puriﬁcation of recombinant humanized antibodies (rhAbs) from
ell culture supernatants is commonly performed by protein A
hromatography followed by two to three additional chromato-
raphic steps to obtain the purity required (Shukla et al., 2007;
ommerfeld and Strube, 2005). Depending on the rhAb the annual
roduction volume is between 6 and 1000 kg/a with the phar-
acy price value between 5000 and 400,000 US$/g (Hagel et al.,
007). In contrast, intravenous immunoglobulin (IVIG) prepara-
ions, which are usually used for the prophylactic prevention of
nfectious diseases in immunodeﬁcient patients, have a signiﬁ-
antly higher annual production volume, almost 100,000 kg/a at
igniﬁcantly lower cost, only ∼91 US$/g (Hagel et al., 2007). The
ower cost can be ascribed to the relatively simple process: The IVIG
reparations are produced from collected human plasma using a
eries of cold ethanol precipitations (CEPs) known as the Cohn pro-
ess (Buchacher and Iberer, 2006; Burnouf, 2007; Cohn et al., 1946,
950; Moure et al., 2003; Radosevich and Burnouf, 2010). Since
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1940s when this process has been ﬁrst established by Cohn and co-
workers, it has undergone several modiﬁcations to improve yield
and purity (Buchacher and Iberer, 2006; Deutsch et al., 1946; Kistler
and Nitschmann, 1962; Oncley et al., 1949). Still, the basic principle,
variation of the ﬁve process parameters pH, ionic strength, ethanol
concentration, protein concentration and temperature for selective
precipitation of different plasma proteins, is still the same for every
plasma fractionation process.
The simplicity and cost-effectiveness of the Cohn process make
CEP an interesting option as an alternative, economic puriﬁcation
strategy for rhAbs from cell culture supernatant compared to other
methods such as counter current loading (Godawat et al., 2012),
counter current extraction (Rosa et al., 2013), or novel adsorp-
tion materials (Barroso et al., 2013; Borlido et al., 2013; Hilbrig
and Freitag, 2012). However, the difference in the starting mate-
rial (Tscheliessnig et al., 2013) makes the straight transfer of the
Cohn process to the puriﬁcation of rhAb from cell culture super-
natant impossible: Despite the recent advances in rhAb titer in the
last decade (Low et al., 2007; Shukla and Thoemmes, 2010) the
concentrations of immunoglobulin (IgG) in human plasma are still
higher (6–14 g/L, (Buchacher and Iberer, 2006)) than for rhAbs from
cell culture supernatant (<5 g/L). Yet, due to the high complexity of
the human plasma a large number of process steps are required
to obtain the IVIG preparations in the required purity; this is at
cost of yield (∼30%) (Buchacher and Iberer, 2006). Also, the IgGs
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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Table 1
Factors and levels used for development of the puriﬁcation strategies.
Factor Levels
– +
pH 6.5 8.5
Salt type NaCl CaCl2
Conductivity No salt added To 40 mS/cm with respective salt8 A. Tscheliessnig et al. / Journal
resent in human plasma are highly heterogeneous, consisting of
 range of different IgGs of various isoelectric points. In contrast
he rhAbs present in the cell culture supernatant share the identi-
al sequence thus are rather homogeneous compared to the IgGs
resent in human plasma (Kayser et al., 2011; Lingg et al., 2012).
nly the different post-translational modiﬁcations observed result
n the observed heterogeneity. This suggests that CEP could be a
otential alternative for the puriﬁcation of rhAbs from cell culture
upernatant.
The advantage of CEP compared to other methods suggested
o replace the conventional chromatography-based puriﬁcation
Gagnon, 2012; Low et al., 2007) is, that besides its simplicity and
ost-effectiveness, it also has a long safety record. IVIG prepara-
ions are produced using human plasma from a large pool of donors.
his necessitates a tight control of potential contaminations with
known and unknown) viruses as well as prions (Buchacher and
berer, 2006; Radosevich and Burnouf, 2010). It has been shown
hat the cold ethanol precipitation, also in combination with other
rthogonal methods, is well capable to reach the required safety
evel (Buchacher and Iberer, 2006; Cai et al., 2002; Foster et al.,
000).
We  present here the development of a puriﬁcation platform
or rhAb from CHO cell culture supernatant using CEP. In order to
vercome co-precipitation of DNA with the rhAb during CEP we
ncluded CaCl2 precipitation, which has been successfully estab-
ished for clearance of not only DNA but also a number of protein
mpurities from the cell culture supernatant (Satzer et al., 2014).
e established a platform based on CEP and CaCl2 precipitation
or the puriﬁcation of four different rhAbs of different isoelectric
oint from CHO cell culture supernatant using a factorial design
lan. The aim was a signiﬁcant HCP reduction while maintaining
ield. Aggregate formation is a permanent issue during CEP (Bull
nd Breese, 1978; van Oss, 1989; Yoshikawa et al., 2012), therefore
he set-up of the CEP was designed to eliminate the detrimental
ffects of ethanol on proteins: good cooling of the suspension was
rovided and ethanol addition was slow to avoid precipitation due
o excess heat caused by mixing of concentrated ethanol with an
queous solution.
. Materials and methods
All chemicals unless given otherwise were purchased from
erck (Darmstadt, Germany). All buffers for the analytical HPLC
uns were prepared using HQ-H2O, ﬁltered through a 0.22 m ﬁlter
nd degassed prior to use.
.1. CHO culture supernatants
Clariﬁed CHO culture supernatants of four rhAbs were provided
y Novartis Pharma AG (Basel, Switzerland). They were stored at
20 ◦C for long-term storage or 4 ◦C for short-term storage. Prior to
se the supernatants were ﬁltered (0.22 m).rhAb1 and rhAb2 are
ntibodies of the same amino acid sequence but expressed in dif-
erent cell lines. Their isoelectric point was around 9.2. rhAb3 and
hAb4 were more acidic antibodies with a pI of 6.7 and 6.8 respec-
ively. rhAb3 is prone to aggregation and was used to evaluate the
ffect that precipitation would have on such an antibody.
.2. Solubility curves
The alcohols used were methanol (Methanol LCMS Chromasolv,
luka), ethanol (Ethanol 96% Emprove exp) and isopropanol (Isor-
opanol LiChrosolv). rhAb3 was used to evaluate if the alcohols
iffer in their behavior to cause aggregation.
Aliquots of 10 ml  of the clariﬁed cell culture supernatant of
hAb3 were transferred into the reactor vessels of an IntegrityTemperature 9 ◦C −10 ◦C
Ethanol concentration 30% (v/v) 40% (v/v)
10 (Thermo Fisher Scientiﬁc) and tempered to 4 ◦C. The respec-
tive alcohol was  added over 1 h to a ﬁnal concentration of 15.0%
(v/v), 22.5% (v/v) or 30.0% (v/v) using a syringe pump (Ismatec,
Wertheim-Mondfeld, Germany). Simultaneously the temperature
was linearly decreased to either 0 ◦C or −5 ◦C. The precipitates were
collected by depth ﬁltration (GD/X, Whatman) and dissolved in
10 ml  of histidine buffer (20 mM histidine, 100 mM NaCl, pH 6.0).
All experiments were performed in triplicates.
2.3. Factorial design plan
The set-up and evaluation of the full factorial design plan was
based on Montgomery (2009). The factors and levels selected are
given in Table 1. The clariﬁed culture supernatants of rhAb1, rhAb2
and rhAb3 were ﬁrst adjusted to the required pH using 12.5% HCl
or 1 M NaOH. If required, 5 M NaCl or 4 M CaCl2 was added to a
ﬁnal conductivity of 40 mS/cm and the pH veriﬁed and amended if
required. Any precipitate forming was  not removed prior to CEP.
The CEP was performed using the Integrity 10 (Thermo Fisher,
Rochford, UK) which is an automated lab reactor with 10 reaction
cells for which temperature and speed of a magnetic stirrer can be
independently adjusted. 2 ml  of the respective solution was  cooled
to 4 ◦C and then 96% (v/v) ethanol, also cooled to 4 ◦C, added to
obtain a ﬁnal concentration of 30% (v/v) or 40% (v/v) respectively.
After 2 h of incubation at 300 rpm the precipitate of each cell was
removed by ﬁltration (0.22 m)  and the supernatant analyzed for
DNA, IgG and total protein. Each set-up was  evaluated in triplicates.
Using the effect estimates obtained a regression model was
applied to calculate the solubility of the rhAbs, DNA  and total pro-
tein within the limits of the factorial design plan applied. This
allowed drafting different puriﬁcation strategies before experi-
mental evaluation. The levels of the factors given in Table 1 were
selected to enable a regression model where a range of different
conditions could be evaluated. For pH the levels were limited by
the isoelectric points of the antibodies used and for ethanol the
range was limited to the concentrations which were evaluated to
result in a high precipitate fraction (see Fig. 1).
2.4. Lab-scale CEP
For the CaCl2 precipitation the respective supernatant or solu-
tion was adjusted to pH 8.5 using 10 M NaOH. Then 5 M CaCl2 was
added to a ﬁnal concentration of 250 mM CaCl2. If required, the pH
amended to pH 8.5 using 10 M NaOH. The precipitate was  removed
by centrifugation (4000 rcf, 15 min, RT). For the CEP supernatant
obtained after CaCl2 precipitation was  adjusted to pH 6.5 using
25% HCl, then transferred to the EasyMax (Mettler Toledo, Gießen,
Deutschland), an automated lab reactor and tempered to 4 ◦C. Using
the integrated syringe pump a 96% (v/v) ethanol stock was  added
over 4 h to obtain a ﬁnal concentration of 25% (v/v). Simultaneously
the temperature was  linearly decreased to −10 ◦C. The solution was
mixed by the integrated over-head stirrer (350 rpm) and tempera-
ture and turbidity monitored by a temperature probe and IR probe
respectively. After incubation for 2 h post ethanol addition the pre-
cipitate was  collected by centrifugation (−10 ◦C, 4000 rcf, 15 min)
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Fig. 1. Solubility curves at 0 ◦C and −5 ◦C show similar behavior for methanol, ethano
re  identical.
nd then dissolved in 20 mM histidine, 100 mM NaCl, pH 6.5. All
recipitations were performed in duplicates.
.5. Initial screening for analytical anion-exchange
hromatography
All experiments were performed using an Äkta Avant 25 at a
ow rate of 4 ml/min and 10 ml/min respectively. The columns
ig. 2. Comparison of analytical SEC chromatogram of dissolved rhAb after precipitation w isopropanol. Analytical SEC chromatograms of the respective dissolved precipitates
used were the CIM disk QA and the CIM disk DEAE (column volume
0.34 ml;  Biaseparation, Ajdovscina, Slovenia) as well as a membrane
adsorber, the Sartobind Q (volume: 0.41 ml,  membrane area 15 cm2
Sartorius, Goettingen, Germany). The column or membranes were
equilibrated with 15 CV equilibration buffer (20 mM Tris, 25 mM
NaCl, pH 8.5). The dissolved rhAb2 precipitate was present in dis-
solution buffer (20 mM histidine, 100 mM NaCl, pH 6.5). If required
it was  adjusted to pH 7.0 or 8.0 with 3 M Tris and/or diluted to a ﬁnal
ith ethanol stocks of different concentration and different speed of ethanol addition.
20 A. Tscheliessnig et al. / Journal of Biotechnology 188 (2014) 17–28
Fig. 3. Impact of the main factors on solubility of rhAb, DNA and protein impurities of the rhAb1 supernatant.
Fig. 4. Impact of the main factors on solubility of rhAb, DNA and protein impurities of the rhAb2 supernatant.
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tFig. 5. Impact of the main factors on solubility of rh
aCl concentration 50 mM or 25 mM.  The concentration of rhAb2
as 0.8 mg/ml  except for buffers containing only 25 mM where the
olution had to be diluted further (ﬁnal: 0.4 mg/ml rhAb2). Bound
ontaminants were eluted using 20 mM Tris, 1 M NaCl, pH 8.0.
.6. Lab scale CEP with subsequent analytical anion-exchange
hromatography
The experiments were performed in triplicates. The CEP pre-
ipitations were performed as described previously, only the 2nd
EP precipitate was dissolved in 10 mM Tris, 25 mM NaCl, pH 8.0
nstead of 20 mM histidine, 100 mM NaCl, pH 6.5. The dissolved
recipitates were then ﬁltered (0.2 m,  25 mm GD/X PVDF syringe
ilter, Whatman). The anion-exchange chromatography was per-
ormed using the Äkta Avant 25 at a ﬂow rate of 4 ml/min. The CIM
isk DEAE was equilibrated with 15 CV 10 mM Tris, 25 mM NaCl,
H 8.0, then the sample loaded and the ﬂowtrough collected for
nalysis. The disk was regenerated using 20 mM Tris, 1 M NaCl, pH
.0.
.7. Analytical protein A chromatography
A method slightly modiﬁed as described by Tscheliessnig and
ungbauer (2009) was used. Brieﬂy, a convective interactive media
CIM) monolithic disk with Staphylococcus Protein A (sProtein A)
s ligand (CIM Protein A HLD, BIA Separations, Ljubljana, Slovenia)
as connected to an Agilent 110 Series (Agilent Technologies Wald-
ronn, Germany). The disk was equilibrated using 30 mM sodium
hosphate, 1000 mM NaCl, pH 7.4 (equilibration buffer) followed
y injection of 25–100 L of ﬁltered (0.22 m) sample. Unbound
roteins were washed out by 0.5 ml  of equilibration buffer and
ound rhAb eluted with 2.0 ml  10 mM HCl (pH 2.0). The elution pro-
le was monitored by measurement of absorbance at 280 nm and
he concentration of rhAb was calculated by automated integrationA and protein impurities of the rhAb3 supernatant.
of the elution peak and comparison to a calibration curve pre-
pared from a polyclonal IgG (Octagam, gift of Octapharma, Vienna,
Austria).
2.8. Analytical SEC
If not mentioned otherwise SEC was performed using a Bio-
SEC3 column (Agilent, Santa Clara, USA). The column and the
respective guard column were connected to an Agilent 1100 Series
(Agilent Technologies, Waldbronn, Germany). The column was
equilibrated (0.2 M sodium phosphate, 0.1 M potassium sulfate,
pH 6.0) at a ﬂow rate of 1.2 ml/min. 100 l of ﬁltered (0.2 m,
Millipore, Carrigtwohill, Ireland) sample was  injected and the UV
absorbance monitored at 280 nm.  Aggregates and high-molecular
weight impurities are deﬁned as peaks observed at an elution
time lower than 7 min  and remaining impurities are deﬁned as
peaks observed at an elution time higher than 9 min. For rhAb4
analytical SEC was performed using the TSK G3000 SWxl column
(Tosoh Bioscience, Tokio, Japan). The column and the respective
guard column were connected to an Agilent 1100 Series (Agilent
Technologies) and tempered to 30 ◦C. The column was  equilibrated
(150 mM potassium phosphate, pH 6.5) at 0.4 ml/min and 10 l of
ﬁltered (0.2 m,  Millipore) sample was injected. The UV absorbance
was monitored at 210 nm.  Aggregates and high-molecular weight
impurities are deﬁned as peaks found at an elution time lower than
20 min  and remaining impurities are deﬁned as peaks observed at
an elution time higher than 25 min.
2.9. DNA quantiﬁcationDNA was quantiﬁed using the Quant-iT PicoGreen DNA kit
(Invitrogen, Paisley, UK) in microplate format according to the man-
ufacturer’s instructions.
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ethod “E” is using 1:4 diluted (with WFI) supernatant.
.10. HCP ELISA
First a microtiter plate (Immuno 96 MicroWell Plates, Max-
Sorb, NUNC, Roskilde, Denmark) was coated with goat anti-CHO
CP antibody (3G-0016-AF, Cygnus, Southport, NC, USA) diluted
:400 in 200 mM sodium carbonate, pH 9.4 overnight at 4 ◦C.
he plates were then blocked with 3% bovine serum albumin
BSA, Sigma–Aldrich, St. Louis, USA) in TBS/Tween (500 mM Tris,
500 mM NaCl, 0.05% (v/v) Tween 20, pH 7.4) for 1 h at 37 ◦C. For
ach plate a duplicate standard curve (1.6–200.0 ng/ml) was  pre-
ared by serial dilution (1:2) of a CHO HCP stock (F553H, Cygnus)
n 1% BSA in TBS/Tween. The samples were diluted likewise and
fter transferring samples and standards to the microtiter pate, it
as incubated for 1 h at 37 ◦C. After incubation with the goat anti-
HO HCP HRP concentrate (3G-0016-AF, Cygnus) diluted 1:2000
n TBS/Tween for 1 h at 37 ◦C the TMB  Peroxidase EIA Substrate
it (Bio-Rad, Hercules, USA) was used as recommended by the
anufacturer for staining. The enzymatic reaction was stopped
y addition of 50 l of 1 N H2SO4 to each well. The absorbance
t 405 nm was measured using a Tecan Inﬁnite F500 plate reader
Tecan, Salzburg, Austria).d “E” are for comparison: method “D” is without modiﬁcation of the supernatant;
3. Results
3.1. Alternative organic solvents
Ethanol is a common precipitant for proteins (Gemili et al.,
2007; Golunski et al., 2011; Wilcockson, 1975) as well as DNA
(Wilcockson, 1975). Its frequently cited advantages are (i) its
miscibility with water, (ii) no formation of explosive gaseous
mixtures under normal working conditions, (iii) it is evaporable
and (iv) chemically inert, has a (v) low toxicity, results in the
(vi) reduction of freezing point and (vii) it is cheap and easily
available. We  also evaluated other alcohols for their applicability
to precipitate IgG from a clariﬁed CHO cell culture supernatant.
We found that methanol and isopropanol have similar efﬁciency
for precipitation (see Fig. 1). However, methanol is toxic and
its application of the puriﬁcation of biopharmaceutical proteins
should be considered with care. We expect a similar behav-
ior for 1-propanol as for isopropanol. Starting with butanol
the miscibility of the alcohols was  too low to be used for
precipitation.
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ethod “I” is using 1:4 diluted (with WFI) supernatant.
.2. Development of cold ethanol precipitation (CEP)
Based on the Cohn process we selected pH, ethanol concentra-
ion and temperature for the factorial design plan. Additionally,
nstead of ionic strength we also included conductivity as factor
nd adjusted it using either sodium chloride or calcium chloride.
e found that it was important to add ethanol at a slow ﬂow rate
o avoid formation of aggregates (see Fig. 2). Addition of ethanol
ver 4 hours ensured that no or only few aggregates formed when
dding 96% (v/v) ethanol.
All experiments were performed in triplicates using the super-
atant of rhAb1–rhAb3. The solubility of IgG, DNA and protein
mpurities under the selected conditions was evaluated by deter-
ining their concentration in the supernatant obtained after
recipitation. The impact of the main factors on the solubility
f DNA, IgG and protein impurities for rhAb1 is found in Fig. 3.
or rhAb2 and rhAb3 the impact of the main factors is found in
igs. 4 and 5, respectively. Similar, the trends of the interactions
f the main factors can be evaluated by plotting the respective
ata (ﬁgure not shown). For all rhAbs we ﬁnd that the main factors
thanol concentration and temperature have a signiﬁcant inﬂuence
n solubility of the respective rhAb. Also we ﬁnd that interactiond “I” are for comparison: method “H” is without modiﬁcation of the supernatant;
of the factor conductivity and temperature affects solubility for all
rhAbs: for higher conductivity a lower temperature is required to
ensure low rhAb solubility. For other main factors or interacting
factors we  ﬁnd no similarity between all rhAbs. From the data it is
however clear, that pH has only little inﬂuence on rhAb solubility
during CEP. Regarding solubility of DNA we  found for all rhAbs that
solubility increased with increasing temperature; for all other fac-
tors and interactions the effect depends on the supernatant used. In
case of the supernatants of rhAb1 and rhAb2 we  ﬁnd that the types
of salt as well as the ethanol concentration have signiﬁcant impact.
Regarding protein impurities the factors having a signiﬁcant impact
on solubility are dependent on the rhAb supernatant evaluated. For
the main factors we  ﬁnd only two factors which give the same trend
for all mAb  supernatants: with increasing salt and increasing tem-
perature the solubility of the protein impurities increases. For the
interacting factors no agreement can be found at all.
In order to obtain a ﬁrst estimation of the possible puriﬁcation
conditions we  used the data obtained from the factorial design
plan to apply a regression model. We  obtained a set of functions
describing the solubility of the respective rhAb, DNA  and protein
impurity for each supernatant. We  then calculated the effect of dif-
ferent puriﬁcation conditions and drafted different puriﬁcations.
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(ig. 8. Different precipitation methods evaluated for rhAb3 supernatant. Method “
ethod “M”  is using 1:4 diluted (with WFI) supernatant.
he aim of each precipitation step was to selectively precipitate
ither the rhAb or DNA and total protein. As comparison we  also
lways evaluated ethanol addition to the supernatant without prior
djustment of conductivity or pH.
We then evaluated different puriﬁcation strategies (see
igs. 6–8) and found that one puriﬁcation strategy, labeled “A” could
e used for all antibodies tested. As given in the table in Fig. 9 we
lso found for rhAb2 that the repeated execution of the puriﬁcation
trategy “A” resulted in a 155× reduction of CHO HCP. Hence we
ontinued to use the repeated execution of puriﬁcation strategy “A”
or CEP.
.3. Lab-scale puriﬁcation
We  performed the CEP puriﬁcation also at larger lab-scale
70 ml)  to verify increase of yield upon up-scaling. With up-scaling
lso minor adjustments of the method were performed: (i) instead
f addition of CaCl2 to a speciﬁc conductivity (29 mS/cm) we esti-
ated the appropriate concentration of CaCl2 (250 mM)  required to
each this conductivity. This simpliﬁed precipitation at large-scale.
ii) We  performed the CaCl2 precipitation at room temperature. InFig. 9. Set-up of puriﬁcation strategy “A” when executed repeatedly. Mass balance
for  repeated execution of puriﬁcation strategy “A”.
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Table  2
Yield, IgG monomer content, purity and HCP concentration of the large lab-scale puriﬁcations (70 ml)  of rhAb1, rhAb2, rhAb3 and rhAb4. Each precipitation was  performed
as  duplicate.
IgG Yield IgG monomer Purity DNA HCP HCP reduction
[g/ml] step/overall [ppm] [ppm] step/overall
rhAb1
Supernatant 1222 1021 54,212
1st  CaCl2 1029 94%/94% 44,641 1.2/1.3
1st  CEP 874 85%/80% 628 6922 6.5/7.8
2nd  CaCl2 684 86%/69% 3157 2.3/17.2
2nd  CEP 636 93%/64% >99.9% >99.9% 557 650 4.9/83.4
rhAb2
Supernatant 2563.4 3037 109,231
1st  CaCl2 2379.4 98%/98% 26,773 4.1/4.1
1st  CEP 2172.4 91.3%/89% 1294 15,224 1.8/7.4
2nd  CaCl2 1991.7 98.1%/88% 3865 3.9/28.9
2nd  CEP 1816.4 91.2%/80% 99.90% 99.90% 350 1202 3.2/92.1
rhAb3
Supernatant 1953 0 0 2659 180,099
1st  CaCl2 1808 99%/99% n.d.
1st  CEP 1649 89%/88% 1336 n.d.
2nd  CaCl2 1487 >99%/88% n.d.
2nd  CEP 1391 94%/83% 89.50% 89.50% 545 8276 9.37/20.0
rhAb4
Supernatant 3322 358 81,752
1st  CaCl2 2826 92%/92% n.d.
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C1st  CEP n.a. n.a. 
2nd  CaCl2 2337 89%/82% 
2nd  CEP 2162 93%/76% 99.40% 
revious experiments we veriﬁed that change of temperature had
o effect on the yield or puriﬁcation efﬁciency of the CaCl2 precipi-
ation (data not shown). (iii) No washing step was used for the CEP
recipitate. Besides for the previously used rhAbs (rhAb1–rhAb3)
he method was also applied for rhAb4.
We monitored the CEP step using an IR probe to measure the
ncreasing turbidity. We  found that the precipitation is a fast, step-
ike process starting at around 17% (v/v) ethanol and −6 ◦C (see
ig. 10).
Fig. 11 gives the analytical SEC and the results of the ﬁnal prod-
ct for the puriﬁcation of rhAb1–rhAb4. A detailed mass balance
an be found in the Table 2. For rhAb1 an overall yield of 64% was
chieved, this could be due to the low IgG concentration in the
upernatant (∼1 g/L) as compared to the other rhAb supernatants.
s around 0.1 g/L stay in solution under the selected conditions
data not shown), we can only expect about 90% overall yield during
ach CEP step. This is in agreement with the data found in Table 2.
dditional losses during the CaCl2 precipitation of the impurities
ig. 10. Temperture proﬁle, IR probe response and ethanol concentration of a typical
EP  step at large lab-scale (70 ml).n.d. n.d.
n.d.
99.40% 80 3702 22.09/48.65
then result in the low overall yield. We  ﬁnd that the puriﬁed rhAb1
(2nd CEP precipitate) is of high purity (>99.9%) and contains no
aggregates. This can also be seen in the chromatogram of the ana-
lytical SEC (Fig. 11). The ﬁnal HCP concentration of 650 ppm results
in an overall HCP reduction of ∼80×.  As can be seen for rhAb1 the
CEP step is more efﬁcient in HCP removal than the CaCl2 precipi-
tation step. However, we found that the CaCl2 precipitation step is
required for an efﬁcient removal of the HCPs (data not shown).
For rhAb2 a higher overall yield was observed (80%) which is
not unexpected considering the higher starting concentration (see
Table 2). Also the puriﬁed rhAb2 has no aggregates and is of high
purity (99.9%). This is also conﬁrmed by analytical SEC (Fig. 11).
The HCP concentration is higher than for rhAb1 but due to the
higher HCP content in the supernatant of rhAb2 a slightly higher
HCP reduction (>90×) is achieved.
For rhAb3 yield is highest among all rhAb supernatants tested
(>83%). However, rhAb3 is prone to aggregation and as can be seen
in Fig. 11 or also in Table 2 a signiﬁcant amount of aggregates can
be found. HCP removal is low, only 20×.
For rhAb4 the puriﬁcation strategy has not been tested prior to
upscale. However we  found that it worked well (Table 2), resulting
in an overall yield of 76% a high purity (>99%) and, as also seen
in Fig. 11, a low aggregate content. We  found that HCP reduction
was relatively low (<50×). This could not be further improved by
modiﬁcation of the CaCl2 precipitation or CEP (data not shown).
3.4. Comparison to protein A chromatography
Comparing our puriﬁcation based on precipitation with a pro-
tein A-based puriﬁcation performed in-house we ﬁnd better HCP
clearance (pA: 5232 ppm; CEP: 650 ppm) and aggregate concentra-
tion (pA: <1.4%; CEP: <0.1%) for rhAb1 (Satzer et al., 2014). However,
the protein A puriﬁcation is not optimized and better HCP and
aggregate clearance could be expected. Follman et al. (Silva et al.,
2012) obtained a reduction to 300 ppm equivalent to a ∼70× reduc-
tion. Yield is in any case higher for the protein A-based puriﬁcation
(84%), which is obvious as for the afﬁnity-based puriﬁcation only
a single puriﬁcation step is required, while for the precipitation-
based puriﬁcation four steps are required. However, we  found an
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Ethanol could also be replaced by methanol or isopropanol
if desired. The method is suited for a continuous operation,
which would further improve the economy of such a processFig. 11. Analytical SEC chromatograms for puriﬁed rhAb1, r
ncrease in yield from 26% at small lab-scale (10 ml)  to 64% at large
ab-scale (70 ml)  and we expect further improvement upon further
p-scaling.
.5. Anion-exchange chromatography (AEX)
We  screened the conditions for AEX of rhAb2 with regards to pH
6.5, 7.0 and 8.0), NaCl concentration (25 mM,  50 mM or 100 mM)
nd column (CIM disk DEAE, CIM disk QA and Sartobrand DEAE).
ighest HCP removal was found for pH 8.0 and 25 mM NaCl using
he CIM disk DEAE (see Fig. 12). We  performed a larger lab-scale
recipitation (70 ml)  including the developed AEX as ﬁnal step. For
econd CEP, previous to the AEX step the precipitate was  dissolved
n the buffer required for AEX (10 mM Tris, 25 mM NaCl, pH 8.0).
etails of the puriﬁcation are found in Fig. 13. We  obtained a yield
f 78% with a low DNA (121 ppm) and HCP (80 ppm) content. Fig. 13
lso gives the SEC chromatogram (TSK G3000 SWxl); a second peak
an be found subsequent to the IgG peak which is caused by the
ample buffer.
. Discussion
We  have developed a puriﬁcation process for rhAbs from clar-
ﬁed CHO culture supernatant using CaCl2 precipitation and cold
thanol precipitation (CEP). We  showed that the process can be
pplied to rhAbs of different isoelectric point. HCP clearance was
n some cases very efﬁcient (80–90×).  A more detailed character-
zation of the HCPs present in the different supernatants might be
elpful in identifying the difference in the HCP proﬁle of the dif-
erent supernatants. Yield was around 60–90% and we  expect it to
ncrease further upon further upscaling. The yield is also dependent
n the initial concentration of antibodies in the supernatant. For
recipitation the residual concentration of antibody in the super-
atant is deﬁned by the precipitation conditions, applied, e.g. pH,, rhAb3 and rhAb4 from large lab-scale (70 ml) experiment.
temperature, salt concentration, precipitant. This concentration is
constant regardless of the initial antibody concentration. Now, if
the initial antibody concentration is high, then this residual non-
precipitated antibody is a smaller fraction than for lower initial
concentrations. Therefore yield will increase with the initial con-Fig. 12. HCP concentration in ﬂowthrough as measured in the screening (pH and
NaCl) of the CIM disk QA, CIM disk DEAE and Sartobind Q.
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pig. 13. Chromatogram of analytical SEC of ﬁnal product (DEAE AEX ﬂowthrough)
nd mass balance for puriﬁcation of rhAb2.
Jungbauer, 2013). In principle the method is also suited for sep-
ration of antibodies produced with other host systems such as
erC.6 (Kuczewski et al., 2011) or even microbial cells such as Pichia
astoris (Maccani et al., 2014).
Additional the CEP for immunoglobulins from human blood
lasma had been developed as a continuous process: In order to
void the Cohn fractionation being carried out batch-wise in ves-
els of 2000–10,000 L a fractionation process based on continuous
mall volume mixing (CSVM) was developed and implemented in
he fractionation center of the Scottish National Blood Transfusion
ervice which was commissioned in 1975 (Foster et al., 1986). A
ruly continuous operation (24 h/day) was also tested over 6 days
nd had a capacity of 338,000 L a year. The potential of a con-
inuous precipitation reactor was therefore clearly demonstrated
Foster et al., 1986). For our process an additional CaCl2 precipita-
ion would need to be implemented. The last step of our puriﬁcation
ethod, AEX, is operated in ﬂowthrough mode, which would be
asily implemented in a continuous process. We  found our process
o be comparable to our in-house protein A puriﬁcation suggesting
hat the CaCl2/CEP puriﬁcation method could be used to replace the
nitial capture step of conventional rhAb puriﬁcation processes. For
hAb2 we have also implemented a ﬁnal chromatographic anion-
xchange chromatography step for additional CHO HCP removal.
ith this step the CHO HCP could be decreased to as low as 80 ppm
ompared to ∼1200–1500 ppm for CaCl2 precipitation/CEP alone.
his data was obtained under laboratory conditions, applying the
onditions required during commercial production (e.g. sanitized
quipment, WFI, . . .)  a higher purity could be expected. In produc-
ion environment validated cleaning procedures minimize risk of
arry over. With increasing size we also expect reduced carry over,
ecause the surface to volume ratio shrinks. The purity was higher
ith antibody with high pI. This is explained by the nature of CHO
CP. A lot of these proteins are in the acidic range and discrimina-
ion due to pH is more difﬁcult.
The method introduced has been established for four different
ntibodies. While we found that the method as described worked
ell for the antibodies selected, it is understood, that adaptation of
his method may  be required to make it suitable for other anti-
odies. With the capabilities provided by automated platforms
Berg et al., 2014; Nfor et al., 2012; Silva et al., 2012; Treier et al.,
012a, 2012b) such a screening process could be easily set up and
rovide the tools for fast process development. We  also tested PEGtechnology 188 (2014) 17–28 27
precipitation and combination of CEP and PEG for rhAB puriﬁcation.
Also these methods result in high purity and yield and a platform
approach could be used for optimization. We  see a big potential in
combing these methods.
5. Conclusion
We have shown the applicability of the cold ethanol precipita-
tion for the puriﬁcation of recombinant antibodies from cell culture
supernatant. The advantage of this process is that the CaCl2/CEP
puriﬁcation method requires only simple equipment such as stirred
tanks and centrifuges, making it an easily scalable process. Also, CEP
is already an established method in the biopharmaceutical indus-
try, being the standard method of plasma fractionation. The lower
costs of the IVIG preparation prepared by the Cohn process as com-
pared to conventional rhAb preparations from CHO supernatants
suggest that the CaCl2 precipitation/CEP could be an improvement
in the production of rhAbs.
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